Placeholder Banner

BIO Applauds FDA Action on AquAdvantage® Salmon

March 8, 2019
Media Contact
BIO logo
202.747.1281

Washington, D.C. (March 8, 2019) – The Biotechnology Innovation Organization (BIO) released the following statement on the action taken today by the U.S. Food & Drug Administration (FDA) which will allow AquaBounty Technologies, an American company, to commercialize its genetically engineered AquAdvantage® Salmon in the U.S. market.

“BIO applauds today’s announcement by FDA, and while long overdue, this milestone paves the way for future innovations that contribute to a more sustainable food supply for a growing world population and lessen the impact on our environment.

“Going forward, BIO will continue to work with FDA to support greater clarity in the regulatory process and an efficient, predictable pathway to product approval. By implementing a transparent, science-based and risk-appropriate regulatory path, the United States and American companies can lead the way in developing biology-driven solutions to society’s biggest challenges.”

The AquAdvantage® Salmon was developed by Massachusetts-based AquaBounty Technologies, a BIO member. It is genetically engineered to reach its market weight in half the time of conventionally raised salmon while using 25 percent less food, thus contributing to more sustainable aquaculture systems.

 

###

 

Discover More
Washington, D.C. (September 22, 2020) –The Biotechnology Innovation Organization (BIO) today presented Sharon Bomer Lauritsen, founder of AgTrade Strategies LLC, former Assistant United States Trade Representative for Agricultural Affairs and…
Washington, D.C. (September 17, 2020) – The Biotechnology Innovation Organization (BIO) announced Dr. Pramod Chaudhari, Executive Chairman of Praj Industries Limited, as the winner of the 2020 George Washington Carver Award for Innovation in…
Washington, D.C. (September 15, 2020) – Next week at BIO IMPACT Digital (Sept. 21-22), Sen. Debbie Stabenow (D-MI) will join a panel of women leaders…